MK-0616 (Enlicitide Decanoate)

· Merck Sharp & Dohme LLC

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MK-0616 (Enlicitide Decanoate), covering 2025-02-17 to 2025-02-17. Get the full timeline:

Most recent: Clinical Trial Update: Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Renal Impairment Study (MK-0616-020) [Phase 1]